AIMT - Nestle Acquiring Aimmune And Other News: The Good Bad And Ugly Of Biopharma September, 21 2020 12:18 AM Aimmune Therapeutics Inc. Aimmune to be acquired by Nestle for $2.6 billion. Mallinckrodt receives a CRL for Terlipressin. Cassava reports positive final data for Alzheimer’s treatment. For further details see: Nestle Acquiring Aimmune, And Other News: The Good, Bad And Ugly Of Biopharma